Biorestorative Therapies, Inc. earnings releases BRTX

Annual Quarterly

Biorestorative Therapies, Inc. last reported quarterly results on Nov 12, 2025, for Q3 FY2025 (the quarter ended Sep 30, 2025): revenue of $11,800 (-94.9% year over year) and diluted EPS of -$0.33. It usually reports 43–44 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 43–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Nov 12, 2025 43 days after quarter end	Q3 FY2025 ended Sep 30, 2025	0 -94.9%	-3 -178.4%	-0.33 -153.8%
Aug 12, 2025 43 days after quarter end	Q2 FY2025 ended Jun 30, 2025	0 +240.4%	-3 +34.1%	-0.30 +40.0%
May 14, 2025 44 days after quarter end	Q1 FY2025 ended Mar 31, 2025	0 -28.6%	-5 -140.2%	-0.64 -93.9%
Nov 13, 2024 44 days after quarter end	Q3 FY2024 ended Sep 30, 2024	0 +660.9%	-1 -122.9%	-0.13 -133.3%
Aug 6, 2024 37 days after quarter end	Q2 FY2024 ended Jun 30, 2024	0 +38.1%	-4 +29.4%	-0.50 +66.0%

Company profile

Industry: Services-Misc Health & Allied Services, NEC (SIC 8090)
Listed as: BRTX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: NV
Headquarters: Melville, NY
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1505497
Former names: Stem Cell Assurance, Inc. (until Aug 16, 2011)

Other Services-Misc Health & Allied Services, NEC companies

All 15 Services-Misc Health & Allied Services, NEC companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.